Shipment of GMP DMT, In Vitro HERG and Genotox Assays Completed, and In Vivo Toxicity Assays Underway Vancouver, British Columbia–(Newsfile Corp. – November 24, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“ Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide an update on its upcoming…

Source

Previous articlePharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus
Next articleSeelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note